Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioventus ( (BVS) ) has issued an update.
On June 3, 2025, Bioventus, Inc. held its Annual Meeting of Stockholders, where approximately 89.76% of the outstanding shares were represented. During the meeting, stockholders elected Class I directors to the Board and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (BVS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.
Spark’s Take on BVS Stock
According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.
Bioventus’s overall score reflects its current financial struggles, with significant leverage and declining revenues posing risks. While the earnings call offers some optimism for future growth, the technical indicators and valuation concerns weigh heavily on the stock’s outlook.
To see Spark’s full report on BVS stock, click here.
More about Bioventus
Bioventus, Inc. operates in the medical technology industry, focusing on developing and commercializing clinically proven treatments that help people heal quickly and safely. The company primarily offers products in orthobiologics, active healing therapies, and surgical solutions, with a market focus on enhancing the lives of patients worldwide.
Average Trading Volume: 426,953
Technical Sentiment Signal: Sell
Current Market Cap: $529M
Learn more about BVS stock on TipRanks’ Stock Analysis page.